Hair-loss treatment stocks emerge as Korea's latest market theme
Hair-loss treatment stocks have emerged as the latest theme in Korea's equity market, drawing investors searching for the next big pharmaceutical trade after the boom in obesity drugs, market watchers said Monday. Shares of JW Shinyak and Samik Pharm jumped 55.48 percent and 22.91 percent over the past week, respectively, as enthusiasm spread across Korean companies seen as having exposure to the…
Hair-loss treatment stocks have become the latest hot topic in Korea's stock market, attracting investors seeking the next big pharmaceutical opportunity after the recent surge in obesity drugs, according to market analysts. Shares of JW Shinyak and Samik Pharm rose by 55.48 percent and 22.91 percent over the past week, respectively, as optimism spread across Korean companies perceived to have exposure to the hair-loss market. Hyundai Pharmaceutical also experienced a 29.06 percent increase.
JW Shinyak, a subsidiary of the JW Group, specializes in prescription drugs available through hospitals, clinics, and pharmacies. Its hair-loss portfolio encompasses both oral and topical treatments, and the company is venturing into hair care cosmetics. Hyundai Pharmaceutical has been active in the Korean hair-loss drug market for 39 years.
Samik Pharm aims to become the next generation in the industry. In January, the company obtained a patent for a platform technology designed to transform once-daily oral hair-loss drugs into long-acting injections administered monthly. These gains were not limited to pharmaceutical companies. Bioneer, a firm developing hair-loss treatments, also contributed to the market's positive sentiment.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Frieze, Kiaf Seoul point to Korea's recovering art market koreatimes.co.kr
